|
OKUYAMA Ryo
Department Ritsumeikan Asia Pacific University College of International Management Position Professor |
|
| Language | English |
| Publication Date | 2024/10 |
| Type | Research paper |
| Peer Review | Peer reviewed |
| Title | Developer and Partnership Differences in COVID-19 and Other Infections: Insights from DNA Vaccines. |
| Contribution Type | Single Work |
| Journal | Journal of Market Access & Health Policy |
| Journal Type | Another Country |
| Volume, Issue, Page | 12(4),pp.317-325 |
| Authorship | Lead author,Last author,Corresponding author |
| Author and coauthor | Ryo Okuyama |
| Details | Historically, vaccine development has relied on public support, while private biopharma has driven innovation in new therapies. During COVID-19, emerging biopharma, in partnership with large corporations and public institutions, rapidly developed vaccines using mRNA and adenoviral vector technologies, highlighting the importance of emerging bipharma and public–private partnerships in advancing new vaccine methods. This study analyzed DNA vaccine development and found that while COVID-19 development relied on emerging biopharma and private–public collaborations, vaccine development for other diseases was primarily led by public organizations. Future vaccine strategies should consider each disease’s unique characteristics. |